Alongside the other members of the Lung PROSPR Research Consortium, PC3I investigators are examining utilization and outcomes of lung cancer screening across diverse populations in five different community-based healthcare systems across the U.S.
The Work of PC3I
Our initiatives are focused on clinical transformation, payment models and affordability, and incentives to change behaviors, harnessing the insights of Penn’s renowned medical researchers, data scientists, healthcare and behavioral economists, and innovators.
We are change agents dedicated to designing, testing, scaling and disseminating innovations in cancer care.
A pilot across Penn thoracic medical oncology outpatient practices will embed a novel clinical pathway tool into the EHR in an effort to reduce variation in cancer treatment, thus reducing costs and improving patient outcomes.
This study examines an innovative solution to reduce time burden for patients with advanced cancer: a text messaging e-triage tool.
Delivering cancer treatment at home has the potential to enhance patient experience and satisfaction while maintaining or improving cancer care quality, to increase the efficiency and productivity of cancer care delivery across Penn’s health system, and to lower health care spending for payers and patients.
The Radiotherapy Comparative Effectiveness Consortium’s National Pragmatic Randomized Trial of Proton Therapy vs. Photon Therapy for Breast Cancer
The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a clinical study comparing two FDA approved radiation therapies — PHoton Therapy vs. PRoton Therapy — for the treatment of breast cancer and enrolls at over 70 radiation therapy practice sites nationwide.